Contact:

Lance Longwell 
IMS Communications     
610.834.5338
llongwell@us.imshealth.com

IMS Health made the following statement today regarding the State of New Hampshire’s announcement that it intends to file an appeal regarding this week’s federal court ruling that strikes down the State’s law banning the commercial use of prescription information.

“We are confident the opinion will be upheld by the First Circuit.  The Judge’s ruling in this matter is comprehensive, well reasoned and based solidly on existing law. Importantly, it upholds the country’s tradition of protecting free speech and the free flow of truthful information.  We continue to believe that patients will benefit from a more transparent, safer and more competitive healthcare system as a result of the Judge’s decision.  We are committed to evidence-based healthcare and believe that suppression of information will be harmful to our society as both citizens and patients.”

About IMS
Operating in more than 100 countries, IMS Health is the world's leading provider of market intelligence to the pharmaceutical and healthcare industries. With $2.0 billion in 2006 revenue and more than 50 years of industry experience, IMS offers leading-edge market intelligence products and services that are integral to clients’ day-to-day operations, including portfolio optimization capabilities; launch and brand management solutions; sales force effectiveness innovations; managed care and consumer health offerings; and consulting and services solutions that improve ROI and the delivery of quality healthcare worldwide. Additional information is available at http://www.imshealth.com.